Related Experiment Videos
Penetrance of hemochromatosis
Jill Waalen1, Vincent Felitti, Terri Gelbart
1Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Insights
Screening for HFE gene mutations, linked to hemochromatosis, shows effects on iron levels and liver health. However, these mutations have minimal impact on other symptoms and lifespan, indicating low clinical penetrance.
Area of Science:
- Medical Genetics
- Gastroenterology
- Public Health Screening
Background:
- Hereditary hemochromatosis is a genetic disorder characterized by excessive iron absorption.
- The HFE gene is a primary genetic factor associated with hereditary hemochromatosis.
- Understanding the clinical significance of HFE gene mutations is crucial for effective screening strategies.
Purpose of the Study:
- To investigate the prevalence and clinical impact of C282Y and H63D mutations in the HFE gene.
- To assess the association between HFE gene mutations and iron indicators, liver disorders, and other iron overload-related symptoms.
- To evaluate the effect of HFE gene mutations on life expectancy.
Main Methods:
- A three-year screening program involving 41,000 subjects.
- Analysis of C282Y and H63D mutations of the HFE gene.
- Monitoring of iron indicators, liver disorders, and other iron overload-related symptoms.
Main Results:
- HFE gene mutations (C282Y and H63D) demonstrate consistent effects on iron indicators.
- These mutations are associated with liver disorders.
- No measurable effect was observed on other iron overload symptoms or life expectancy.
Conclusions:
- The C282Y and H63D mutations of the HFE gene have a significant impact on specific health markers but limited clinical penetrance.
- The low clinical penetrance necessitates careful consideration of cost-benefit and risk-benefit ratios for HFE gene mutation screening programs.
Abstract:
We undertook a three-year screening program for mutations of the HFE gene among 41,000 subjects attending the Kaiser Permanente Health Appraisal Center in San Diego, California. Our results show that the C282Y and H63D mutations of the HFE gene associated with hemochromatosis have measurable and consistent effects on iron indicators and are associated with liver disorders, but have no measurable effect on other iron overload-related symptoms and life-expectancy. The very low clinical penetrance of the HFE mutations must be taken into account in calculating cost/benefit and risk/benefit ratios in screening for hemochromatosis.